Vermillion Presents Results Supporting Clinical Utility of Vasclir PAD Test | GenomeWeb

Vermillion last week reported results demonstrating the utility of its Vasclir protein biomarker test for peripheral artery disease.

In a poster at the Society for Vascular Medicine's annual meeting in Minneapolis, researchers led by Stanford professor of medicine John Cooke presented results from a 1,025-subject, multi-center prospective study that found the Vasclir test was able to identify 85 percent of PAD patients missed by the Framingham Risk Score – a conventional measure of risk for cardiovascular disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.